-
First Generation Disease-Modifying Therapies Pose Low Infection Risk in MS
A large group study showed that first-generation disease-modifying therapies (DMTs) do not increase the infection risk in multiple sclerosis (MS) patients.
Many of the DMTs used to reduce the risk of relapse in MS target the immune system and cause a suppression of the inflammatory response. Although helpful in treating the disease, these therapies may also increase the risk of developing subsequent infections.
Many of the clinical trials that assess adverse events associated with DMTs only look at the short-term risk these treatments may pose.
According to the Canadian research team, this study is the first large group study to look at the long-term effects of DMTs on infection risk in MS patients.
The study, “Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study,” was published in the Journal of Neurology, Neurosurgery & Psychiatry.
Researchers used population-based health administrative data from British Columbia, Canada. They identified 6,793 people with MS, most (73.6 percent) of them women. The average age at the time of the first MS-related event was 45.4 years.
Read more here: “First Generation Disease-modifying Therapies Pose Low Infection Risk in MS, Study Finds“
Did you know about this risk of infection for MS patients? Share your thoughts.
Sorry, there were no replies found.
Log in to reply.